Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Ngaimisi E et al. | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. | 2014 | J. Antimicrob. Chemother. | pmid:25096076 |
Bodin K et al. | Antiepileptic drugs increase plasma levels of 4beta-hydroxycholesterol in humans: evidence for involvement of cytochrome p450 3A4. | 2001 | J. Biol. Chem. | pmid:11514559 |
Bodin K et al. | Metabolism of 4 beta -hydroxycholesterol in humans. | 2002 | J. Biol. Chem. | pmid:12077124 |
Hasan M et al. | Rapid LC-MS/MS method for the determination of 4-hydroxycholesterol/cholesterol ratio in serum as endogenous biomarker for CYP3A activity in human and foals. | 2016 | J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. | pmid:27565568 |
Suzuki Y et al. | Significant increase in plasma 4β-hydroxycholesterol concentration in patients after kidney transplantation. | 2013 | J. Lipid Res. | pmid:23833241 |
Honda A et al. | Highly sensitive quantification of key regulatory oxysterols in biological samples by LC-ESI-MS/MS. | 2009 | J. Lipid Res. | pmid:18815436 |
Breuer O | Identification and quantitation of cholest-5-ene-3 beta,4 beta-diol in rat liver and human plasma. | 1995 | J. Lipid Res. | pmid:8656065 |
Mao J et al. | Strategy for CYP3A Induction Risk Assessment from Preclinical Signal to Human: a Case Example of a Late-Stage Discovery Compound. | 2017 | Pharm. Res. | pmid:28815392 |
Diczfalusy U et al. | 4Beta-hydroxycholesterol is a new endogenous CYP3A marker: relationship to CYP3A5 genotype, quinine 3-hydroxylation and sex in Koreans, Swedes and Tanzanians. | 2008 | Pharmacogenet. Genomics | pmid:18300941 |
Niemi M et al. | Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin. | 2006 | Pharmacogenet. Genomics | pmid:16847425 |